ABSTRACT
Objective To explore the expression of miRNA-155 (miR-155) in CD19+B lymphocytes in Uygur patients with chronic lymphocytic leukemia (CLL), and to analyze its clinical significance. Methods Peripheral blood(10-15 ml) samples of 30 Uygur CLL patients, 20 Han CLL patients, 10 Han healthy people and 10 Uygur healthy people were collected.Mononuclear cells were isolated and B lymphocytes were purified by using CD19+magnetic-bead system. Total RNA was extracted from CD19+B lymphocytes. The expression of miR-155 was measured by using TaqMan probe method. All the results were analyze combined with the clinical data of patients. Results The expression level of miR-155 in Han and Uygur CLL patients had no statistical difference(5.994±1.156 vs.5.856±1.359,t =0.556,P=0.710), which was significantly higher than that in the healthy controls(t = 18.612, P < 0.01; t = 17.817, P < 0.01). There were no statistical differences in the expression levels of miR-155 in CLL patients regarding to nationalities, gender, age, Binet staging, Rai staging, expression of CD38 (all P> 0.05). The expression level of miR-155 had a significant statistical difference between ZAP-70 negative group and ZAP-70 positive group(5.7 ± 1.1 vs. 6.5 ± 1.4,t =1.575,P =0.029). The expression level of miR-155 also had a statistical difference between mutated immunoglobulin heavy chain variable region (IGHV) and unmutated IGHV (5.3 ± 1.1 vs. 6.5 ± 1.1, t = 0.210, P= 0.001).The expression level of miR-155 was 5.4 ± 1.2, 5.7 ± 0.7, and 6.6 ± 1.5 in the favorable prognosis group, moderate prognosis group and poor prognosis group respectively(F=3.609,P=0.035); The expression levels of miR-155 had significant differences between moderate group and poor prognosis group (P = 0.032), favorable group and poor prognosis group (P= 0.007). Conclusions The expression of miR-155 in Han and Uygur CLL patients has no significant difference.High-level expression of miR-155 is associated with the poor prognosis of CLL patients.